Edwards Lifesciences Corporation (NYSE:EW) is reporting second quarter earnings results on Thursday 23rd July 2020, after market close.
The consensus estimates from Thomson Reuters are income of $ 0.17 per share.
For the full year, analysts predict revenues of $ 4232.81 million, while looking forward to income of $ 1.63 per share.
The Company Outlook
Revenue for 2Q20 are expected in a range of $ 700.00 million ~ $ 900.00 million
Full Year 2020 topline are forecasted in a range of$ 4,000.00 million ~ $ 4,500.00 million, where as bottomline are predicted in a range of $ 4.75 ~ $ 5.25 per share
Click Here For More Historical Outlooks Of Edwards Lifesciences Corporation
Previous Quarter Performance
Edwards Lifesciences Corporation outlined income for the first quarter of $ 1.51 per share, from the revenue of $ 1,129.00 million. The quarterly earnings grew 14.39 percent while revenues improved 13.70 percent compared with the same quarter last year.
Street analysts expected Edwards Lifesciences Corporation to report income of $ 1.33 per share on revenue of $ 1083.85 million for the first quarter. The bottom line results beat street analysts by $ 0.18 or 13.53 percent, at the same time, top line results outshined analysts by $ 45.15 million or 4.17 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Edwards Lifesciences Corporation
Stock Performance
According to the previous trading day, closing price of EW was $ 77.91, representing a 51.25 % increase from the 52 week low of $ 51.51 and a 5.62 % decrease over the 52 week high of $ 82.55.
The company has a market capital of $ 49.55 billion and is part of the Healthcare sector and Medical Devices industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”EW” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Recent Analyst recommendations
On 29th June 2020, maintained by Morgan Stanley at Overweight rating, with $ 83.00 target price.
On 2nd June 2020, maintained by Credit Suisse Group at Outperform rating, with $ 88.00 target price.
On 1st June 2020, maintained by Morgan Stanley at Overweight rating, with $ 83.00 target price.
Conference Call
Edwards Lifesciences Corporation will be hosting a conference call at 5:00 PM eastern time on 23rd July 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.edwards.com
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; and cardiac cannula devices, as well as various procedure-enabling platforms to advance minimally invasive surgery.
